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Abstract
Background
BPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis.
While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under
heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (pro-
thrombotic) and the NOS-substrate L-arginine (antithrombotic), were little investigated. Ob-
jective. To investigate the effect of L-NAME and L-arginine on hemostatic parameters, and
to reveal the effects of BPC 157 on the L-NAME- and L-arginine-induced hemostatic actions
under different pathological condition: tail amputation without or with anticoagulants, hepa-
rin or warfarin.
Methods
Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were
used in rats. Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination.
Results
After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 μg/kg, 10 ng/
kg, i.p., i.v. (heparin), 10 μg/kg i.g. (warfarin)) always reduced bleeding time and/or haemor-
rhage and counteracted thrombocytopenia. As for L-NAME and/or L-arginine, we noted: L-ar-
ginine (100mg/kg i.p.)–rats: more bleeding, less/no thrombocytopenia; L-NAME (5 mg/kg i.
p.)-rats: less bleeding (amputation only), but present thrombocytopenia; L-NAME+L-arginine-
rats also exhibited thrombocytopenia: L-NAME counteracted L-arginine-increased bleeding,
L-arginine did not counteract L-NAME-thrombocytopenia. All animals receiving BPC 157 in
addition (BPC 157μg+L-NAME; BPC 157μg+L-arginine, BPC 157μg+L-NAME+L-arginine),
exhibited decreased haemorrhage and markedly counteracted thrombocytopenia.
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Conclusions
L-NAME (thrombocytopenia), L-arginine (increased haemorrhage) counteraction and BPC
157 (decreased haemorrhage, counteracted thrombocytopenia) with rescue against two dif-
ferent anticoagulants, implicate a BPC 157 modulatory and balancing role with rescued
NO-hemostatic mechanisms.
Introduction
This study further extends and clarifies the effect of the stable gastric pentadecapeptide BPC
157 on hemostasis [1,2] with addition of N(G)-nitro-L-arginine methylester (L-NAME) and L-
arginine and heparin and warfarin in rats.
NO is an endogenously produced vasodilator and is largely implicated in hemostatic mecha-
nisms [3–9] while, in tail amputation and heparin-/warfarin-administration models, both the NO-
synthase (NOS)-blocker, L-NAME (thought to have a prothrombotic effect) [3] and NOS-sub-
strate, L-arginine [presented with an antithrombotic effect) [3] were little investigated. The simulta-
neous counteraction of these two NO-mediated opposite effects in vivo has never been addressed.
To counteract the consequences of L-NAME and/or L-arginine administration with the dis-
turbed hemostasis, we administered the stable gastric pentadecapeptide BPC 157 [1,2,10–26]
not only due to its special effect on hemostasis [1,2], but also owing to a particular beneficial
combining [1,2,10–14], wound healing capacity [1,2,10–17] and particular interaction with
NO-system [14,15,18–26]. Previously, BPC 157 as an originally anti-ulcer peptide was imple-
mented in inflammatory bowel disease trials [10–15], and now multiple sclerosis [16], lethal
dose (LD1) could be not achieved [10–16]. As mentioned, this unusual combining effect in he-
mostasis was recently evidenced with bleeding/thrombocytopenia after amputation, with or
without anticoagulant and aspirin administration, abdominal aorta anastomotic site-thrombo-
sis, both being counteracted [1,2]. Thereby, a particular cluster of effects on the events ensuing
after loss of vascular integrity, is evident [1,2,14,15].
Wound healing capacity in different tissues [1,2,10–17] (including blood vessels) (i.e., stim-
ulation of the early growth response 1 (egr-1) gene and its co-repressor nerve growth factor
1-A binding protein-2 (naB2) [17] also responsible for cytokine and growth factor generation
and thereby, early extracellular matrix (collagen) and blood vessel formation [17]) and endo-
thelium protection [1,2,14,15] were implicated in these counteracting effects.
Also, interactions with NO-system are shown in different models and various species
[12,13,18–26]. As an illustrative analogy for counteraction of the opposite effects of L-NAME
and L-arginine in haemorrhage, we should emphasize that the particular effects of BPC 157 on
blood pressure [18,20,25] and the anti-arrhythmic effect [18–21] include antagonization of
both L-NAME (hypertension) and L-arginine (hypotension) [25] and counteraction of
endothelin serum increase [20]. Note, endothelin per se, inhibited platelet aggregation and
caused subarachnoid hemorrhage [27,28].
Thus, it was likely that after tail amputation in rats, with/out heparin and warfarin adminis-
tration, BPC 157 would counteract the consequences of administration of the NOS-blocker,
L-NAME (i.e., prothrombotic effect and thereby thrombocytopenia) and/or NOS-substrate, L-
arginine (i.e., antithrombotic effect and thereby more bleeding) [29–31].
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Materials and Methods
Animals
Male Albino Wistar rats were used in all of the experiments (10 rats per experimental group
and interval). The study was approved by the Local Ethics Committee at School of Medicine
(University of Zagreb, Zagreb, Croatia) and experiments were assessed by observers unaware
of the given treatment.
Drugs
As previously [1,14,15] medication, without carrier or peptidase inhibitor, included stable gas-
tric pentadecapeptide BPC 157 (a partial sequence of the human gastric juice protein BPC,
freely soluble in water at pH 7.0 and in saline). It was prepared as a peptide with 99% (HPLC)
purity (1-des-Gly peptide was the main impurity; manufactured by Diagen, Ljubljana, Slovenia,
GEPPPGKPADDAGLV, M.W. 1419) (in dose and application regimens as described before
[1,14,15]. Likewise, in dose and application regimens as described before heparin (Belupo, Cro-
atia), warfarin (Martefarin (Orion Pharma, Finland)), L-NAME (Sigma, USA) and L-arginine
(Sigma, USA) dissolved in saline were used as well [1,14,15].
Bleeding procedures, heparin, warfarin application and medication
Bleeding was monitored as described before [1], until blood flow stopped for a complete 30-s
interval or till the end of 60 min period. In deeply anaesthetised rats (placed in ventral position)
the tail was transected with a surgical scalpel 3 cm from the tip (and submerged into a tube
with 15 ml of saline at room temperature in vertical position) and the duration and amount of
bleeding were measured to evaluate the hemostatic effect of the agents or saline administration.
The blood samples assessment was carried precisely as described before [1] (Table 1).
Table 1. The blood samples assessment, laboratory methods used in the study.
Parameters Methods/Reagents Optimum
specimens/ Tested
within
Analyzers Units
Prothrombin time (PT) Performed according to the technique by Quick using
human placental thromboplastin (Thromborel S, Siemens
Healthcare Diagnostics Products GmbH, Marburg,
Germany)
Plasma/ 2 hours Automated coagulation analyzer
BCS XP System (Siemens,
Marburg, Germany)
ratio
Activated partial
thromboplastin time
(APTT)
Performed by using Actin FS (Dade Actin FS Activated
PTT Reagent, Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany) containing the puriﬁed soy
phosphatides
Plasma/ 2 hours Automated coagulation analyzer
BCS XP System (Siemens,
Marburg, Germany)
ratio
Thrombin time (TT) Performed according to the instructions from
manufacturer using bovine thrombin (BC Thrombin
Reagent, Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany)
Plasma/ 2 hours Automated coagulation analyzer
BCS XP System (Siemens,
Marburg, Germany)
sec
Fibrinogen
concentration (FIB)
Determinated by a modiﬁcation of Clauss' coagulometric
method using bovine thrombin (Multiﬁbren U, Siemens
Healthcare Diagnostics Products GmbH, Marburg,
Germany)
Plasma/ 2 hours Automated coagulation analyzer
BCS XP System (Siemens,
Marburg, Germany)
g/L
Platelet count (PLT) Performed by using Coulter principle (impedance)
(Beckman Coulter Reagents)
Whole blood/ 2
hours
Automated Coulter HmX
Hematology Analyzer (Beckman
Coulter Inc., Florida, USA)
109/L
Hematocrit (HTC) Performed by directly measuring from RBC histogram Whole blood/ 2
hours
Automated Coulter HmX
Hematology Analyzer (Beckman
Coulter Inc., Florida, USA)
L/L
doi:10.1371/journal.pone.0123454.t001
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In addition, platelet counts were corrected with hematocrit to avoid errors that may be
caused by animals bleeding, and were expressed as a percentage of baseline for each time point
of the tested groups. To obtain the hematocrit-corrected platelet count (X) we used the follow-
ing formula: X = (h1xp1 / HxP) x 100, wherein each symbol denotes the following: h1: hemato-
crit of the sample, p1: platelet count of the sample, H: mean hematocrit value of the normal
range in healthy animals (= 0.435), P: mean platelet count value of the normal range in healthy
animals (= 875). HxP result was considered as a baseline of 100%.
Finally, using our own research values determined in healthy rats, prothrombin time (PT)
ratio 1.25–1.45, activated partial thromboplastin time (APTT) ratio 0.38–0.51, thrombin time
(TT) 30–50 sec, fibrinogen concentration (FIB) 1.5–2.0 g/L, platelet count (PLT) 650–1100
x109/L, hematocrit (HTC) 0.38–0.49 L/L were considered as the normal range [1].
Amputation only
BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg), given alone or
combined, were applied intraperitoneally, at 30 minutes before amputation while controls re-
ceived simultaneously an equivolume of saline (5ml/kg intraperitoneally).
Amputation associated with heparin administration
Heparin (10 mg/kg) was given intravenously at 30 minutes before the bleeding procedure. As
a medication, we applied BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100
mg/kg) alone and/or combined, intravenously, immediately after intravenous heparin ad-
ministration, while controls received simultaneously an equivolume of saline (0.5 ml/kg
intravenously).
Amputation associated with warfarin administration
Warfarin was given intragastrically (1.5 mg/kg) once daily for 3 consecutive days, with the last
challenge at 3 hours before the bleeding procedure. BPC 157 (10 μg/kg, 10 ng/kg) was given im-
mediately after any warfarin challenge, intragastrically while controls received simultaneously
an equivolume of saline (5.0 ml/kg intragastrically). We applied L-NAME (5 mg/kg), L-argi-
nine (100 mg/kg) given per se or combined with each other, intraperitoneally, at 30 minutes
before amputation.
Statistical analyses
Statistical analyses of the quantified data were performed by analysis of variance (ANOVA).
Post-hoc comparisons were appraised using the conservative Bonferroni/Dunn test. Data are
presented as the mean ± standard deviation (SD). Values of P<0.05 were considered
statistically significant.
Results
Here, in normal rats, after tail amputation (spontaneous bleeding for 20 minutes, fall in platelet
count without any failure of coagulation parameters) the previous effects of BPC 157 (reduced
bleeding, no thrombocytopenia) [15] were confronted with that of L-arginine (prolonged
bleeding without thrombocytopenia) and L-NAME (reduced bleeding, thrombocytopenia
present), given alone and/or combined. Then, these effects were confronted with administra-
tion of anticoagulants without or with amputation; heparin (extensive bleeding and blood loss,
prominent fall in platelet count, drastic prolongation of PT-, APTT-, TT- values) or warfarin
(extensive bleeding and blood loss, prominent fall in platelet count, drastic prolongation of
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PT-, APTT- values) (Table 2, Table 3 and Table 4). These effects were specifically assessed as
follows (in addition, platelet counts were additionally corrected with hematocrit to avoid errors
that may be caused by animals bleeding (Fig 1)).
BPC 157-rats
Specifically, BPC 157, 10 μg/kg, 10 ng/kg regimens, exhibited a consistent counteracting effect
(i.e., markedly reduced the bleeding time, blood loss and also counteracted: acute thrombocyto-
penia in rats with amputation only, in heparin-rats or warfarin-rats), prolonged APTT-, TT-
values (heparin-rats), but not PT-values (warfarin-rats)).
L-arginine-rats, L-NAME-rats, L-NAME+L-arginine-rats
Alone, L-arginine prolonged bleeding time (rats with amputation only) and increased the
amount of bleeding (heparin-rats, warfarin-rats) while L-NAME reduced bleeding time (rats
with amputation only). L-NAME+L-arginine (combined) exhibited a decrease in bleeding
amount and laboratory values in comparison to controls (amputation only) or control-heparin
and control-warfarin groups. Commonly, controls (amputation only, heparin-rats and warfa-
rin-rats) exhibited thrombocytopenia. L-arginine counteracted thrombocytopenia (L-arginine-
rats with amputation only and L-arginine-heparin-rats are without thrombocytopenia, L-argi-
nine-warfarin-rats are with thrombocytopenia). Contrary to this, L-NAME-rats or L-NAME
+L-arginine-rats consistently exhibited thrombocytopenia.
BPC 157+L-arginine, BPC 157+L-NAME, BPC 157+L-arginine+L-NAME
BPC 157+L-arginine-rats
BPC 157+L-arginine-rats exhibited shorter bleeding times than corresponding controls after
amputation only; amount of bleeding being even less than that of control-heparin-rats or con-
trol-warfarin-rats, in addition to attenuated thrombocytopenia after warfarin administration
Table 2. Normal rats.
Tail amputation Bleeding time Amount of bleeding PLT before PLT after HCT before HCT after PT APTT TT FIB
min mL x109/L x109/L L/L L/L ratio (PR) ratio sec g/L
Control 18±3 1.92±1.1 853±173 605±35 0.446±0.03 0.430±0.04 1.30±0.22 0.45± 0.16 34± 12 1.6± 0.22
BPC ug 7±2* 0.21±0.06* 820±167 685± 22* 0.461±0.03 0.453±0.03 1.32±0.25 0.41± 0.17 40± 11 1.8± 0.17
BPC ng 8±2* 0.24±0.04* 831±178 675± 17* 0.454±0.04 0.446±0.03 1.35±0.21 0.42± 0.11 41± 13 1.7± 0.19
L-arginine 29±4* 1.63±1.2 781±123 702± 30* 0.497±0.03 0.476±0.03 1.29±0.21 0.64± 0.18 35± 9 1.8± 0.23
L-NAME 7±2* 0.75±0.15* 677± 105* 601±40 0.481±0.04 0.454±0.03 1.28±0.19 0.66± 0.21 30± 8 1.8± 0.18
L-NAME+ L-
arginine
21±3 0.8±0.24* 695±94* 442± 15* 0.482±0.05 0.468±0.03 1.24±0.22 0.51± 0.13 46± 14 1.8± 0.21
L-arginine+BPC
157 ug
9±2* 0.57±0.11* 801±189 694± 39* 0.506±0.04 0.490±0.04 1.28±0.21 0.49± 0.17 39± 11 1.8± 0.27
L-NAME+ BPC
157 ug
8±2* 0.40±0.12* 758±122 654± 25* 0.472±0.03 0.465±0.04 1.30±0.22 0.49± 0.18 40± 10 1.8± 0.19
L-NAME+L-
arginine+ BPC
157 ug
10±3* 0.30±0.09* 788±133 655± 31* 0.479±0.03 0.466±0.03 1.34±0.23 0.5± 0.13 48± 13 1.8± 0.18
Tail amputation, bleeding time, amount of bleeding, PLT, HCT, PT, APTT, TT, FIB, values in normal rats (10 rats at least per group) with amputation
challenged with BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) given alone and/or together,applied intraperitoneally, at 30
minutes before amputation while controls received simultaneously an equivolume of saline (5ml/kg intraperitoneally). Mean ± SD,
*P<0.05 at least vs. control.
doi:10.1371/journal.pone.0123454.t002
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and counteracted thrombocytopenia after amputation only, or amputation and heparin- or
warfarin-administration.
BPC 157+L-NAME rats
BPC 157+L-NAME rats exhibited shorter bleeding times with lesser bleeding amounts than
corresponding controls after amputation only; consistently no thrombocytopenia (amputation
only) or attenuated thrombocytopenia in heparin- and warfarin-rats, along with lesser bleeding
amounts than corresponding control-heparin- and control-warfarin-rats.
BPC 157+L-NAME+L-arginine-rats
BPC 157+L-NAME+L-arginine-rats after amputation only, or heparin or warfarin administra-
tion, exhibited a consistent attenuation of thrombocytopenia, along with lesser bleeding time
and/or amount, than corresponding controls.
On the other hand, unlike in BPC 157-rats (BPC 157 given alone), PT-values remained pro-
longed (warfarin-rats), here, after heparin, or warfarin, BPC 157+L-arginine-rats, BPC 157+-
L-NAME-rats, BPC 157+L-arginine+L-NAME-rats exhibited no reduced bleeding time and no
effect on prolonged PT-, APTT-, TT- values (heparin-rats).
Discussion
BPC 157 has been shown to exert beneficial effects against different pathological conditions
[1,2,10–26], it induced gastroprotective, analgesic and anti-inflammatory wound healing
Table 3. Heparin rats.
Heparin 10 mg/kg i.v. Bleeding
time
Amount of
bleeding
PLT
before
PLT
after
HCT
before
HCT after PT APTT TT FIB
Tail amputation min mL x109/L x109/L L/L L/L ratio
(PR)
ratio sec g/L
Control >60 8.82± 2.2 654± 75 426±
105
0.448±
0.02
0.380
+ 0.03
0.87
±0.15
4.07±
1.21
>150 1.5± 0.24
BPC ug 31± 8* 5.08± 1.3* 768± 93* 600±
122*
0.465±
0.03
0.439
+ 0.03*
0.91
±0.17
2.46±
1.16*
91± 14* 1.6± 0.17
BPC ng 35± 9* 5.45± 1.1* 788± 88* 611±
133*
0.457±
0.03
0.434
+ 0.04*
0.93
±0.20
2.00±
1.05*
101±
21*
1.5± 0.21
L-arginine >60 11.5± 3.4* 784±
110*
698±
51*
0.426±
0.02
0.356±
0.03
0.33±
0.06
>5.7 >150 1.1± 0.20
L-NAME >60 8.0± 2.1 727± 80* 479± 62 0.426±
0.04
0.380±
0.03
0.35±
0.08
>5.7 >150 1.2 ± 0.19
L-NAME+ L-arginine >60 8.10± 2.8 819± 79* 498± 77 0.437±
0.03
0.411±
0.04
0.39
±0.09
>5.7 >150 1.0± 0.15
L-arginine+ BPC 157 ug >60 7.3± 1.5* 852±
130*
721±
89*
0.424±
0.04
0.338±
0.02
0.38
±0.08
>5.7 >150 1.4± 0.16
L-NAME+ BPC 157 ug >60 5.5± 1.3* 844±
155*
601±
95*
0.420±
0.03
0.364±
0.03
0.35
±0.07
>5.7 >150 1.3± 0.16
L-NAME+L-arginine+ BPC
157 ug
>60 5.1± 1.4* 800±
129*
658±
83*
0.414±
0.05
0.381±
0.03
0.41
±0.10
>5.7 >150 1.2± 0.16
Tail amputation, bleeding time, amount of bleeding, PLT, HCT, PT, APTT, TT, FIB values in heparin (10 mg/kg intravenously) challenged rats (10 rats at
least per group) when treated with BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone or combined, intravenously,
immediately after intravenous heparin while controls received simultaneously an equivolume of saline (0.5 ml/kg intravenously). Mean ± SD,
*P<0.05 at least vs. control.
doi:10.1371/journal.pone.0123454.t003
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effects [1,2,10–17], also effective against experimental colitis [10–16] and showing a particular
interaction with the NO-system [14,15,18–26]. Recently, we demonstrated the effect of BPC
157 against bleeding/thrombocytopenia after amputation, with or without anticoagulant and
aspirin administration and abdominal aorta anastomotic site-thrombosis [1,2].
Thus, as a proper extension to the disturbed NO-system in hemostasis [3–9], the present
work showed that L-NAME-induced thrombocytopenia and L-arginine-induced increased
hemorrhage. These were counteracted by BPC 157, indicating the modulatory and balancing
role of BPC 157 with rescued NO-hemostatic mechanisms.
Also, for the consistently reduced amount of bleeding in BPC 157-rats [1,2], the illustrative
insight might be the reduced bleeding time evidence, affected by platelet function. Thus, resolv-
ing a hemostatic defect, the hallmark of which is a markedly prolonged bleeding time, BPC 157
reduced the bleeding times in the tail amputation model, heparin and partly warfarin rats, but
unlike in normal rats, did not reduce bleeding time in heparin and warfarin rats when previ-
ously L-arginine or L-NAME was given. Therefore, with respect to BPC 157, L-arginine and
L-NAME, heparin and warfarin, we demonstrated a complex and particular interaction.
In the normal rats, L-NAME reduced bleeding time (and induced thrombocytopenia and
thereby, the NOS-blocker-prothrombotic effect), L-arginine prolonged bleeding time (thereby
showing the NOS-substrate-antithrombotic effect) [29–31]. Consequently, changing these ef-
fects, we likely revealed, a particular action of L-arginine and a particular action of L-NAME
on heparin and warfarin, thus far not demonstrated in amputation rat models. With respect to
BPC 157, they might both augment heparin and warfarin effects and thereby BPC 157 would
Table 4. Warfarin rats.
Warfarin 1.5 mg/kg i.g. once daily for 3
consecutive days
Bleeding
time
Amount of
bleeding
PLT
before
PLT
after
HCT
before
HCT
after
PT APTT TT FIB
Tail amputation min mL x109/L x109/L L/L L/L ratio
(PR)
ratio sec g/L
Control >60 6.58± 1.2 612± 72 302± 79 0.441±
0.04
0.364±
0.02
<0.05 2.86±
0.42
62± 6 1.5±
0.15
BPC ug 48.6± 15* 5.52± 1.4* 693± 68* 456±
116*
0.461±
0.03
0.417±
0.02*
<0.05 2.81±
0.38
60± 7 1.7±
0.25
BPC ng >60 5.65± 1.1* 706± 88* 418±
105*
0.465±
0.02
0.420±
0.03*
<0.05 2.83±
0.47
58± 8 1.5±
0.21
L-arginine >60 7.8± 1.4 638± 89 525±
98*
0.521±
0.06
0.455±
0.04
<0.05 2.03±
0.36
59.9±
8
1.9±
0.19
L-NAME >60 8.0± 1.8 654± 49 346± 59 0.454±
0.03
0.413±
0.03
<0.05 2.60±
0.39
62.6±
7
1.8±
0.17
L-NAME+ L-arginine >60 7.0± 1.7 483± 87* 283± 35 0.467±
0.04
0.415±
0.03
<0.05 2.68±
0.34
60.6±
8
1.8±
0.21
L-arginine+ BPC 157 ug >60 4.9± 0.6* 650± 105 514±
119*
0.476±
0.04
0.472±
0.04
<0.05 2.03±
0.38
59.8±
8
1.6±
0.17
L-NAME+ BPC 157 ug >60 5.0± 0.9* 637± 88 461±
105*
0.475±
0.04
0.415±
0.02
<0.05 1.74±
0.29
60.1±
7
1.6±
0.15
L-NAME+L-arginine+ BPC 157 ug >60 4.5± 0.7* 612± 79 493±
113*
0.501±
0.05
0.481±
0.03
<0.05 1.92±
0.31
78.3±
12
1.8±
0.18
Tail amputation, bleeding time, amount of bleeding, PLT, HCT, PT, APTT, TT, FIB values in warfarin rats. Warfarin was given intragastrically (1.5 mg/kg)
once daily for 3 consecutive days, with the last challenge was at 3 hours before the bleeding procedure. BPC 157 (10 μg/kg, 10 ng/kg) was given
immediately after any warfarin challenge, intragastrically while controls received simultaneously an equivolume of saline (5.0 ml/kg intragastrically). We
applied L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone or combined, intraperitoneally, at 30 minutes before amputation. Mean ± SD,
*P<0.05 at least vs. control.
doi:10.1371/journal.pone.0123454.t004
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have a changed effect (however, as emphasized, BPC 157 always reduced the amount of bleed-
ing). Or, more likely, it could be that their effects are both interfering with that of BPC 157.
Likely, this might also be the supportive part to the general interaction. Namely, very similar
interactions of BPC 157 and the NO system, with both L-NAME and L-arginine, have been
demonstrated by a large number of other previous studies [14,15,18–26]. For instance, counter-
action of both the L-arginine-induced disturbance and L-NAME-induced disturbance was
seen, while maintaining blood pressure against both L-arginine (hypotension) and L-NAME
(hypertension) (note, BPC 157 by itself does not affect basal blood pressure values [25] and
likewise, BPC 157 by itself does not affect basal coagulation/platelets values [1]). Thus, this
analogy might be the principal advantage for this and previous studies [14,15,18–26], with a
challenge in methodology and in general, since in other studies (not related to this model)
L-NAME-thrombocytopenia antagonization was not attempted [3–9,32], nor were L-arginine
and L-NAME simultaneously investigated.
Furthermore, we could argue that with the prolonged bleeding time, specifically disturbed
coagulation factors, with heparin (less) and warfarin (more), would affect BPC 157, L-arginine
and L-NAME. Or, more likely, their effects are in general more resistant to that of heparin and
less to that of warfarin, regardless of the more haemorrhage in heparin rats.
Illustratively, heparin still induced the full effectiveness of BPC 157 in both doses of applica-
tion (μg, ng); thrombocytopenia was present only with L-NAME. L-arginine rats did not
exhibit thrombocytopenia.
Fig 1. Hematocrit-corrected platelet counts (X) before, and after bleeding period.Hematocrit-corrected
platelet counts (X) before, and after bleeding period: (a) in normal rats, BPC 157 (10 μg/kg, 10 ng/kg),
L-NAME (5 mg/kg), L-arginine (100 mg/kg) given alone and/or together,applied intraperitoneally, at 30
minutes before amputation while controls received simultaneously an equivolume of saline (5ml/kg
intraperitoneally); (b) in heparin (10 mg/kg intravenously) challenged rats when treated with BPC 157 (10 μg/
kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone or combined, intravenously, immediately after
intravenous heparin while controls received simultaneously an equivolume of saline (0.5 ml/kg
intravenously); (c) in warfarin rats (warfarin given intragastrically (1.5 mg/kg) once daily for 3 consecutive
days, with the last challenge was at 3 hours before the bleeding procedure). BPC 157 (10 μg/kg, 10 ng/kg)
was given immediately after any warfarin challenge, intragastrically while controls received simultaneously an
equivolume of saline (5.0 ml/kg intragastrically). We applied L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone
or combined, intraperitoneally, at 30 minutes before amputation. Mean ± SD, *P<0.05 at least vs. control, 10
rats at least per group.
doi:10.1371/journal.pone.0123454.g001
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Contrary to this, particular with warfarin are: a lesser effectiveness of BPC 157 (smaller dose
not effective on bleeding time, but still affects amount of bleeding and thrombocytopenia); not
only with L-NAME-rats, but also those treated with L-arginine there was an initial marginal
thrombocytopenia up to a very prominent thrombocytopenia after amputation, and both ex-
hibited unaffected warfarin-bleeding amounts. Thus, with warfarin, thrombocytopenia is the
common end result of the L-NAME and/or L-arginine administration. In consequence, with
the thrombocytopenia and haemorrhage, the expected lack of NO-suppression of platelet ag-
gregation [33], the acceleration and amplification of the induced pattern of platelet activation
resulting in platelet exhaustion [9] (L-NAME), grossly correspond to the suggested inhibition
of platelet aggregation, by direct action on an intraplatelet constitutive calcium-dependent
NOS [33–35] (L-arginine). In either case, particularly considering the sustained warfarin bleed-
ing, even when L-arginine actually attenuated thrombocytopenia, the disturbed NO-hemostat-
ic system [27,30,31] is the entity which has to be further rescued. Thereby, it is important that
thrombocytopenia appeared also in warfarin L-NAME+L-arginine-rats and that it is attenuat-
ed by the addition of BPC 157 (L-NAME+L-arginine+BPC 157-rats) and reduced the amount
of bleeding. Likewise, the addition of BPC 157 to the L-NAME (L-NAME+BPC 157-rats) or to
the L-arginine (L-arginine+BPC 157-rats), equally reduced the amount of bleeding. Thereby,
we argue that the better hemostasis was achieved with BPC 157 administration, the balanced
role of the L-arginine and of the L-NAME and the more rescued NO-hemostatic mechanisms.
The supportive argument may be that BPC 157 by itself induces NO-release (demonstrated
from gastric mucosa supernatant), like L-arginine, but also in conditions where L-arginine is
not working [14].
Consequently, whatever the fundamental mechanism of BPC 157 beneficial effects, there
was a BPC 157-induced counteraction of the two different anticoagulants and of the L-NAME
and the L-arginine. Together, these counteractions could obviously suggest an alternative
common pathway.
Possibly, the consistent endothelium protection during advanced healing processes in dif-
ferent wounds of various tissues, including blood vessels [1,2,10–17], associated with the coun-
teraction of the L-NAME-induced disturbances as well as the counteraction of the L-arginine-
induced disturbances, obtained with the same BPC 157 dose range [14,15,18–26], should likely
compete with the prominent endothelium effect of the heparin-impaired endothelial nitric
oxide (NO) synthesis [36] as well as warfarin endothelium damage [37]. Finally, as emphasized,
BPC 157 beneficial effects include stimulation of egr-1 gene and its co-repressor gene naB2
[17], also responsible for cytokine and growth factor generation and thereby, early extracellular
matrix (collagen) and blood vessel formation [17]. Egr-1 functions as a master switch activated
by ischemia to trigger expression of pivotal regulators of inflammation, coagulation and vascu-
lar hyperpermeability [38]. Thus, BPC 157 by naB2 regulation could represent a mechanism to
guarantee a suited transient EGR-1 activity following injury [39]. Supporting may also be the
BPC 157-induced decrease of the inflammatory mediators, leukotriene B4 (LTB4), thrombox-
ane B2 (TXB2), and myeloperoxidase (MPO), in both serum and inflamed tissue [40], largely
implicated in heparin-induced platelet activation, the adhesion of leukocytes to the endotheli-
um and concomitant increase in vascular permeability [41], prolongation of the bleeding time
[42] while low-molecular-weight heparin enoxaparin causes systemic MPO activation [43].
Lastly, implicated in coagulation disorders as well as in anaphylaxis [44], in response to stimuli
such inflammation and trauma, mast cells degranulate and consequently release heparin [45]
while BPC 157 pretreatment significantly prevented mastocyte infiltration [46]. Also, BPC 157
rescued already advanced anaphylactoid reactions caused by mastocytes degranulation when
given after the challenge [47].
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In conclusion, these results accord with the previous NO-system studies [10–26] and the
particular BPC 157 effect on hemostasis [1,2]. Along with the BPC 157 safety evidence (LD1
could be not achieved, and without side effects in patients and healthy subjects) [10–16], these
likely suggest that BPC 157 could solve the lack of specific antagonist as a major concern asso-
ciated with the anticoagulant clinical use.
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